Core Viewpoint - The article discusses the challenges and market dynamics of the influenza vaccine industry in China, highlighting the low vaccination rates and the dominance of antiviral medications in sales compared to vaccines [3][4]. Group 1: Market Performance - In 2024, the sales figures for major influenza vaccine companies in China are as follows: Hualan Biological (10.73 billion), Jindike (808.03 million), and Zhonghui Biological (260 million) [4]. - The total sales of these four companies (Hualan, Jindike, Zhonghui, and Baike Biological) do not exceed 1.6 billion, which is significantly lower than the sales of Dongyang Sunshine Pharmaceutical's antiviral drug Oseltamivir, which reached approximately 2.6 billion [6]. Group 2: Economic Burden of Influenza - The economic burden of influenza for outpatient patients ranges from 801 to 1,320 yuan, while for hospitalized patients, it can be between 9,832 and 23,833 yuan [6]. Group 3: Vaccination Challenges - The low vaccination rate in China is attributed to public misconceptions about the necessity and effectiveness of vaccines, as well as concerns about side effects [8][9]. - "Vaccine hesitancy" is identified as a significant barrier to increasing vaccination rates, with public education and improved access to vaccination services recommended as necessary measures [9].